Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 4/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13729882 | 0.81 | BRD9 (0.41) | HTR2CHTR2ACA1CA2ACHE | |
| SCHEMBL11661554 | 0.81 | CHRM1 (0.42) | HTR2CALDH1A1HTR2A | |
| SCHEMBL11658276 | 0.78 | PDE3B (0.40) | HTR2CALDH1A1HTR2AACHEHTR5A | |
| SCHEMBL11658394 | 0.78 | ALDH1A1 (0.53) | ALDH1A1ALOX12NPC1 | |
| SCHEMBL13729633 | 0.74 | MAPKAPK2 (0.37) | HTR2CALDH1A1HTR2ACA1CA2 | |
| SCHEMBL11657761 | 0.74 | CHRM1 (0.42) | HTR2CALDH1A1HTR2A | |
| SCHEMBL31158608 | 0.74 | HTR2C (0.49) | HTR2CHTR2ACA1CA2ACHE | |
| SCHEMBL2258698 | 0.74 | HTR2C (0.53) | HTR2CALDH1A1HTR2ACA1CA2 | |
| SCHEMBL315233 | 0.73 | PDE3B (0.41) | HTR2CALDH1A1HTR2AACHEHTR5A | |
| SCHEMBL315232 | 0.73 | PDE3B (0.41) | HTR2CALDH1A1HTR2AACHEHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2705039-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | HTR2C 3015/4885ALDH1A1 3348/4885HTR2A 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.